Business Update: Pressure BioSciences, Inc. (OTCQB: PBIO)

• Report rights infringement
• published: 22 Jul 2016
• views: 798

Pressure BioSciences Unveils Barocycler 2320EXT at Major Scientific Meeting; Next Generation PCT-based Instrument Expected to be Centerpiece of the Recently Announced Co-Marketing Agreement with Global Life Sciences Analytical Technologies Leader SCIEX Compelling Advantages of Pressure BioSciences' Patented PCT Platform Prominently Featured in Multiple Presentations at Same International Conference SOUTH EASTON, Mass., July 13, 2016 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced the unveiling of the newest addition to their product line based on their patented and powerful pressure cycling technology ("PCT") platform, the Barocycler 2320EXTREME ("2320EXT"). The product unveiling took place during the recent annual conference of the American Society for Mass Spectrometry ("ASMS") in San Antonio, TX. The Company also announced that scientists from six separate research groups made presentations on the Company's PCT-based product line at the same international conference. Results presented indicated that the Company's PCT-based instruments and consumables, when used in the preparation of samples for mass spectrometric analysis, resulted in critically enabling qualitative and quantitative improvements and/or improved time or cost efficiency. Presentations were made by scientists from the Children's Medical Research Institute (Sydney, Australia), the Johns Hopkins University School of Medicine, the Center for Food Safety and Applied Nutrition - Food and Drug Administration (FDA/CFSAN), Northwestern University, and Pressure BioSciences together with Protifi LLC. The ASMS Conference is one of the largest annual meetings of mass spectrometry professionals worldwide. The Company took advantage of this opportunity to unveil the Barocycler 2320EXTREME. This newest addition to PBI's product line was designed with a number of new and enhanced features and benefits that should enable scientists better access to the biomolecules (e.g., proteins, lipids, nucleic acids) in samples being studied, with the potential to result in new biological insights and discoveries, and rapid growth for PBI. The Barocycler 2320EXT is expected to become the centerpiece of the recently announced co-marketing agreement with global life sciences analytical technologies leader SCIEX. Dr. Nate Lawrence, Vice President of Marketing and Sales, said: "Our participation in the recent ASMS Conference greatly exceeded our expectations, both in relation to the unveiling of the new Barocycler 2320EXT, and to the number and content of presentations by well-respected scientific groups on the advantages/benefits of our PCT-based product line when used in the critical area of sample preparation." Dr. Lawrence continued: "We had nearly 1,000 attendees visit our exhibition booth and hospitality suite. A number of these visitors were genuinely interested in learning about the advantages of PCT, and the features and benefits of the new Barocycler 2320EXT. We are actively following up with these contacts, and expect that some of these scientists/groups will become PBI customers in the near future." Mr. Richard T. Schumacher, President and CEO of PBI, commented: "In addition to the successful unveiling of the Barocycler 2320EXT, five well-respected research groups presented data supporting the advantages of the PCT Platform, including our colleagues at CMRI in Sydney, Australia. CMRI will be analyzing approximately 70,000 tumor biopsy samples over the next seven years with PCT-SWATH, the method that combines PBI's PCT platform for sample preparation with SCIEX's SWATH Acquisition. This combination of technologies has the potential to vastly accelerate proteomic research, which could increase the opportunities to discover new biomarkers, potentially resulting in significant improvements in healthcare worldwide."